Asgard Therapeutics described preclinical work supporting AT-108, an adenoviral vector therapy designed to reprogram tumor cells into cDC1-like antigen-presenting cells. The approach uses intratumoral delivery of Ad5-PIB encoding PU.1, IRF8, and BATF3, aiming to restore antigen presentation that can drive resistance to checkpoint blockade. Asgard reported durable antitumor efficacy and synergy with immune checkpoint inhibitors in the presented preclinical context, targeting a recurring mechanism of immune escape in “cold” tumors. The strategy aligns with a growing interest in turning the tumor microenvironment into an immunologically competent state rather than relying solely on PD-(L)1 axis modulation. AT-108’s readouts add to the set of therapies competing for differentiation via pathway-specific microenvironment rewiring in oncology development programs.